Group 1: Company Performance - LeKai Film reported a revenue of 960 million yuan and a net profit of -86 million yuan for the first three quarters of 2025, indicating a potential annual loss [1] - The company stated that its main business remains unchanged and that production activities are operating normally without significant external changes [1] - LeKai Film's stock has seen a significant increase of over 35% since December 31, 2025, primarily driven by speculation in the commercial aerospace sector [1] Group 2: Industry Developments - OpenAI launched the ChatGPT Health feature to address health-related inquiries, linking smart devices and planning diet and exercise, similar to Alibaba's Ant Aifuku [4][5] - The global AI healthcare market is projected to grow from approximately 26.65 billion USD in 2024 to about 505.59 billion USD by 2033, with a compound annual growth rate of 38.8% [8] - AI healthcare applications are expected to accelerate due to ongoing policy support and technological advancements, with significant investment opportunities emerging in the sector [7] Group 3: Institutional Interest - Over 30 AI healthcare-related stocks have been identified, with several companies actively engaging with investors regarding their AI healthcare strategies [9] - Notable companies like Lingying Medical and Kailing Medical have received substantial institutional attention, with Lingying Medical being surveyed by 317 institutions [12] - Financing activities have increased for companies such as Haoyuan Pharmaceutical and Shuyupingmin, with over 50 million yuan in additional funding since the fourth quarter of 2025 [12]

每经AI快讯，有投资者在投资者互动平台提问：上海航天精密机械研究所曾采购"航天专用蓝盒乐凯胶 片"，是否用于航天航空？ 乐凯胶片（600135.SH）1月8日在投资者互动平台表示，工业探伤片（工业射线胶片）核心应用领域是 工业无损检测，作用机理在各种具体的应用场景中并无差别，客户可根据产品功能，自行选择应用领 域。 （文章来源：每日经济新闻） ...

证券日报网讯12月30日，乐凯胶片（600135）在互动平台回答投资者提问时表示，工业探伤片(工业射 线胶片)核心应用领域是工业无损检测，作用机理在各种具体的应用场景中并无差别，客户可根据产品 功能，自行选择应用领域。 ...